Keyphrases
Inflammatory Bowel Disease
100%
Serological Response
100%
Anti-tumor Necrosis Factor (anti-TNF)
100%
Response to COVID-19
100%
COVID-19 mRNA Vaccine
100%
Healthy Controls
71%
BNT162b2
42%
Adverse Events
28%
Patient-controlled
28%
Vaccine Response
28%
Drug Levels
28%
Anti-spike
28%
Israeli
14%
High Risk
14%
Disease Activity
14%
Infection Rate
14%
Safety Profile
14%
Timing of Administration
14%
Functional Activity
14%
Inhibitory Activity
14%
Antibody Level
14%
Vaccine Dose
14%
2-dose
14%
Second Dose
14%
Pfizer-BioNTech
14%
Vaccine Booster
14%
Anti-spike Antibody
14%
Vaccine-preventable Diseases
14%
Messenger
14%
Rate-2
14%
Anti-TNF Drugs
14%
Medicine and Dentistry
COVID-19
100%
Tumor Necrosis Factor
100%
mRNA Vaccine
100%
Patient with Inflammatory Bowel Disease
100%
Adverse Event
18%
Inflammatory Bowel Disease
18%
Diseases
9%
Infection
9%
Disease Activity
9%
Prospective Study
9%
Infection Rate
9%
Booster Dose
9%
Necrosis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Tumor Necrosis Factor
100%
mRNA Vaccine
100%
Adverse Event
18%
Infection
9%
Diseases
9%
Infection Rate
9%
Prospective Study
9%
Disease Activity
9%
Necrosis
9%
Immunology and Microbiology
COVID-19
100%
Inflammatory Bowel Disease
100%
Tumor Necrosis Factor
100%
Spike
27%
Drug Concentration
18%
Infection Rate
9%
Booster Dose
9%